Douglas Klaiber

Co-founder And Chief Commercial Officer at Q-VANT Biosciences

Douglas Klaiber is an accomplished executive with extensive experience in the pharmaceutical and biotechnology industries. Currently serving as the Chief Executive Officer of Q-VANT Biosciences since January 2022, Klaiber leads efforts to address supply chain challenges for QS-21 and Quillaja-based saponin adjuvants, utilizing next-generation technology to significantly increase production capabilities. Since April 2019, Klaiber has also held the CEO position at Urobiome Therapeutics, focusing on the development of innovative therapies for urinary microbiome-related diseases. Prior roles include CEO at Naturex-DBS LLC and Decas Botanical Synergies, as well as Sr. Director of Marketing at Taqua Systems. Klaiber holds a B.S. in Mechanical Engineering from Penn State University and an MBA from the University of Pennsylvania (Wharton).

Location

Melrose, United States

Links


Org chart


Teams

This person is not in any teams


Offices